RT Journal Article SR Electronic T1 Tubal histopathological abnormalities in BRCA1/2 mutation carriers undergoing prophylactic salpingo-oophorectomy: a case–control study JF International Journal of Gynecologic Cancer JO Int J Gynecol Cancer FD BMJ Publishing Group Ltd SP 41 OP 47 DO 10.1136/ijgc-2021-003153 VO 32 IS 1 A1 Federica Sina A1 Chiara Cassani A1 Chiara Comerio A1 Elena De Ponti A1 Francesca Zanellini A1 Martina Delle Marchette A1 Gaia Roversi A1 Marta Jaconi A1 Eloisa Arbustini A1 Mario Urtis A1 Cristina Dell’Oro A1 Benedetta Zambetti A1 Cristiana Paniga A1 Eleonora Acampora A1 Serena Negri A1 Sara Lazzarin A1 Stefania Cesari A1 Arsenio Spinillo A1 Joanne Kotsopoulos A1 Robert Fruscio YR 2022 UL http://ijgc.bmj.com/content/32/1/41.abstract AB Objective To describe tubal histopathological abnormalities in women with germline BRCA1/2 mutations and in controls.Methods Consecutive women with BRCA1/2 mutations undergoing bilateral salpingo-oophorectomy between 2010 and 2020 in two centers (San Gerardo Hospital, Monza and San Matteo Hospital, Pavia) were considered in this analysis and compared with controls who had the same surgical procedure for benign conditions. Frequency of p53 signature, serous tubal intraepithelial carcinoma, and high-grade serous ovarian cancer were compared between the two groups.Results A total of 194 women with pathogenic BRCA1/2 mutations underwent prophylactic salpingo-oophorectomy. Of these, 138 women (71%) had a completely negative histological examination, while in 56 (29%) patients an ovarian or tubal alteration was reported. Among controls, 84% of patients had a p53wt signature, while 16% had a p53 signature. There was no difference in the frequency of a p53 signature between cases and controls; however, women with BRCA1/2 mutations were more likely to have pre-malignant or invasive alterations of tubal or ovarian epithelium (p=0.015). Among mutation carriers, older age both at genetic testing and at surgery was associated with an increased risk of having malignancies (OR=1.07, p=0.006 and OR=1.08, p=0.004, respectively). The risk of malignancy seems to be increased in patients with a familial history of high-grade serous ovarian cancer. Previous therapy with tamoxifen was significantly more frequent in patients with malignant lesions (40.0% vs 21.3%, p=0.006).Conclusion We found that a p53 signature is a frequent finding both in BRCA1/2 mutation carriers and in controls, while pre-invasive and invasive lesions are more frequent in BRCA1/2 mutation carriers. Genetic and clinical characteristics are likely to affect the progression to malignancy.Data are available upon reasonable request.